Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025

Company has alignment with U.S. Food and Drug Administration (“FDA”) on key design elements of planned Phase 3 study of ELI-002

Read more at globenewswire.com